Antibodies

04 Apr 2020 I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19)
04 Apr 2020 XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients
04 Apr 2020 Nucala (mepolizumab) is the first anti-IL5 biologic to report positive phase 3 results in patients with nasal polyps
04 Apr 2020 Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years
04 Apr 2020 U.S. Food and Drug Administration (FDA) Approves Reblozyl® (luspatercept-aamt) , the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
03 Apr 2020 Biotest is developing with Trimodulin a COVID-19 therapy for patients with a severe course of the disease
03 Apr 2020 Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19
03 Apr 2020 Henlius Novel Anti-EGFR Monoclonal Antibody Demonstrated Favorable Safety and Tolerability Profile in Its Phase 1 Clinical Study
03 Apr 2020 Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19
03 Apr 2020 Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)
03 Apr 2020 Celltrion’s COVID-19 Antiviral Treatment Enters the Next Phase of Development
02 Apr 2020 University Hospital Basel, Switzerland Transfuses First Two COVID-19 Patients With INTERCEPT Treated Coronavirus Convalescent Plasma
02 Apr 2020 Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene
02 Apr 2020 Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA
02 Apr 2020 Merck Announces KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
01 Apr 2020 Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation
01 Apr 2020 InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology
01 Apr 2020 Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19
01 Apr 2020 Ostrich Pharma USA Produces Antibodies to Block the Virus that Causes COVID-19
01 Apr 2020 EUSA Pharma and Papa Giovanni XXIII Hospital, Italy, Provide Interim Analysis Data for Siltuximab-Treated COVID-19 Patients from the SISCO Study
01 Apr 2020 Takeda Receives Positive CHMP Opinion for ADCETRIS in Combination w/ CHP for Adult Patients with Previously Untreated sALCL
31 Mar 2020 I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea
31 Mar 2020 GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19
31 Mar 2020 Mersana Therapeutics Reports Updated Data from the XMT-1536 Phase 1 Dose Escalation Study
30 Mar 2020 Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top